233 related articles for article (PubMed ID: 37036479)
1. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
Fung MHM; Lang BHH
Eur Radiol; 2023 Sep; 33(9):6534-6544. PubMed ID: 37036479
[TBL] [Abstract][Full Text] [Related]
2. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
3. Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves' disease.
Lang BH; Woo YC; Chiu KW
Eur Radiol; 2019 Dec; 29(12):6690-6698. PubMed ID: 31209622
[TBL] [Abstract][Full Text] [Related]
4. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, management and outcomes of Graves' disease-real life data.
Hussain YS; Hookham JC; Allahabadia A; Balasubramanian SP
Endocrine; 2017 Jun; 56(3):568-578. PubMed ID: 28478488
[TBL] [Abstract][Full Text] [Related]
6. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.
Vigone MC; Peroni E; Di Frenna M; Mora S; Barera G; Weber G
J Endocrinol Invest; 2020 May; 43(5):595-600. PubMed ID: 31713721
[TBL] [Abstract][Full Text] [Related]
7. Definitive treatment of Graves' disease in children and adolescents.
Król A; Czarniecka A; Jarząb B
Endokrynol Pol; 2021; 72(6):661-665. PubMed ID: 34855196
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study.
Brito JP; Payne S; Singh Ospina N; Rodriguez-Gutierrez R; Maraka S; Sangaralingham LR; Iñiguez-Ariza NM; Montori VM; Stan MN
Thyroid; 2020 Mar; 30(3):357-364. PubMed ID: 31973681
[No Abstract] [Full Text] [Related]
9. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
[TBL] [Abstract][Full Text] [Related]
11. [Radioiodine versus surgery in the treatment of Graves' hyperthyroidism].
Jukić T; Stanicić J; Petric V; Kusić Z
Lijec Vjesn; 2010; 132(11-12):355-60. PubMed ID: 21294325
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
13. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
14. Long-term thionamide antithyroid treatment of Graves' disease.
Azizi F; Abdi H; Amouzegar A; Habibi Moeini AS
Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101631. PubMed ID: 35440398
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed Graves' disease.
Liu X; Wong CKH; Chan WWL; Tang EHM; Woo YC; Liu SYW; Lam CLK; Lang BHH
Br J Surg; 2022 Mar; 109(4):381-389. PubMed ID: 35136950
[TBL] [Abstract][Full Text] [Related]
16. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
18. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
[TBL] [Abstract][Full Text] [Related]
19. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
20. Hyperthyroidism. Current treatment guidelines.
Gittoes NJ; Franklyn JA
Drugs; 1998 Apr; 55(4):543-53. PubMed ID: 9561343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
